OticPharma Appoints Keith Katkin Chair
This article was originally published in Scrip
Executive Summary
OticPharma Ltd., a privately held specialty pharmaceutical company focused on acquiring and developing innovative therapies for ear, nose, and throat disorders, has named Keith A. Katkin chair of its board of directors. Katkin is currently president CEO and a member of the board of directors of Avanir Pharmaceuticals. Prior to joining Avanir, he was vice president of commercial development for Peninsula Pharmaceuticals, playing a key role in the concurrent initial public offering and ultimate sale of the company to Johnson and Johnson.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.